267876-26-6 Usage
Uses
Used in Pharmaceutical Industry:
1H-Pyrrolo[3,2-b]pyridine-5-methanamine(9CI) is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique polycyclic aromatic structure and methanamine group may contribute to the development of new drugs with specific therapeutic properties.
Used in Synthetic Chemistry:
1H-Pyrrolo[3,2-b]pyridine-5-methanamine(9CI) is used as a building block in the synthesis of complex organic molecules. Its versatile structure allows for further functionalization and modification, enabling the creation of novel compounds with potential applications in various fields, such as materials science, agrochemistry, or specialty chemicals.
Check Digit Verification of cas no
The CAS Registry Mumber 267876-26-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,6,7,8,7 and 6 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 267876-26:
(8*2)+(7*6)+(6*7)+(5*8)+(4*7)+(3*6)+(2*2)+(1*6)=196
196 % 10 = 6
So 267876-26-6 is a valid CAS Registry Number.
267876-26-6Relevant articles and documents
Anticoagulant contrast media
-
Page/Page column 15-16, (2010/02/15)
The present invention provides novel anticoagulant contrast agents, which comprise an organic scaffolding moiety, an organic anticoagulant moiety, and an imaging moiety. The invention also provides anticoagulant contrast media and methods of visualizing internal structures utilizing the novel anticoagulant contrast agents and anticoagulant contrast media.
Azaindoles: Moderately basic P1 groups for enhancing the selectivity of thrombin inhibitors
Sanderson, Philip E. J.,Stanton, Matthew G.,Dorsey, Bruce D.,Lyle, Terry A.,McDonough, Colleen,Sanders, William M.,Savage, Kelly L.,Naylor-Olsen, Adel M.,Krueger, Julie A.,Lewis, S. Dale,Lucas, Bobby J.,Lynch, Joseph J.,Yan, Youwei
, p. 795 - 798 (2007/10/03)
Starting from a 2-amino-6-methylpyridine P1 group and following a strategy of enlarging it whilst reducing its polarity, we have developed a series of potent, moderately basic azaindoles which are intrinsically much more selective for thrombin versus tryp
